Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019
Precision medicine is a patient-specific approach that integrates all relevant clinical, genetic
and biological information in order to optimise the therapeutic benefit relative to the …
and biological information in order to optimise the therapeutic benefit relative to the …
Minimal clinically important differences in pharmacological trials
PW Jones, KM Beeh, KR Chapman… - American journal of …, 2014 - atsjournals.org
The concept of a minimal clinically important difference (MCID) is well established. Here, we
review the evidence base and methods used to define MCIDs as well as their strengths and …
review the evidence base and methods used to define MCIDs as well as their strengths and …
Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary
The Global Initiative for Chronic Obstructive Lung Disease (GOLD) has published the
complete 2023 GOLD report, which can be freely downloaded from its web page (www …
complete 2023 GOLD report, which can be freely downloaded from its web page (www …
Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary
CF Vogelmeier, GJ Criner, FJ Martinez… - American journal of …, 2017 - atsjournals.org
This Executive Summary of the Global Strategy for the Diagnosis, Management, and
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …
Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 …
Dyspnoea: a multidimensional and multidisciplinary approach
L Laviolette, P Laveneziana - European Respiratory Journal, 2014 - Eur Respiratory Soc
Dyspnoea is a debilitating symptom that affects quality of life, exercise tolerance and
mortality in various disease conditions/states. In patients with chronic obstructive pulmonary …
mortality in various disease conditions/states. In patients with chronic obstructive pulmonary …
A review of national guidelines for management of COPD in Europe
M Miravitlles, C Vogelmeier, N Roche… - European …, 2016 - Eur Respiratory Soc
The quality of care can be improved by the development and implementation of evidence-
based treatment guidelines. Different national guidelines for chronic obstructive pulmonary …
based treatment guidelines. Different national guidelines for chronic obstructive pulmonary …
Хроническая обструктивная болезнь легких: федеральные клинические рекомендации по диагностике и лечению
АГ Чучалин, СН Авдеев, ЗР Айсанов… - …, 2022 - journal.pulmonology.ru
Аннотация В настоящее время хроническая обструктивная болезнь легких (ХОБЛ)
является глобальной проблемой и одной из ведущих причин смерти в мире. Терапия …
является глобальной проблемой и одной из ведущих причин смерти в мире. Терапия …
Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)
C Vogelmeier, R Buhl, O Burghuber, CP Criée… - …, 2018 - thieme-connect.com
Das vorliegende Dokument ist eine Neufassung und Aktualisierung der Leitlinie zur
Diagnostik und Therapie von Patienten mit COPD, die die bisherige Version aus dem Jahr …
Diagnostik und Therapie von Patienten mit COPD, die die bisherige Version aus dem Jahr …
Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD–2019 update of evidence
In this guideline update, we highlight important and new findings related to pharmacological
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …
Dual combination therapy versus long‐acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta …
Background Long‐acting bronchodilators such as long‐acting β‐agonist (LABA), long‐
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …
acting muscarinic antagonist (LAMA), and LABA/inhaled corticosteroid (ICS) combinations …